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SUMMARY
Cellular information processing via reversible protein
phosphorylation requires tight control of the localiza-
tion, activity, and substrate specificity of protein
kinases, which to a large extent is accomplished by
complex formation with other proteins. Despite their
critical role in cellular regulation and pathogenesis,
protein interaction information is available for only a
subset of the 518 human protein kinases. Here we
present a global proteomic analysis of complexes
of the human CMGC kinase group. In addition to
subgroup-specific functional enrichment and modu-
larity, the identified 652 high-confidence kinase-
protein interactions provide a specific biochemical
context for many poorly studied CMGC kinases.
Furthermore, the analysis revealed a kinase-kinase
subnetwork and candidate substrates for CMGC
kinases. Finally, the presented interaction proteome
uncovered a large set of interactions with proteins
genetically linked to a range of human diseases,
including cancer, suggesting additional routes for
analyzing the role of CMGC kinases in controlling
human disease pathways.
INTRODUCTION
Reversible phosphorylation of proteins is a key mechanism to
regulate the activity of enzymes and control the localization
and stability of proteins and their interactions with other proteins.
These events in turn control information processing by cellular
signal pathways to regulate metabolism, cell division, apoptosis,
andmore. Protein phosphorylation is catalyzed by 518members
of the human protein kinase family, representing one of the
largest protein families in human cells (Manning et al., 2002).
Deregulation of human kinases has been causally linked to a va-
riety of human malignancies (Lahiry et al., 2010; Manning, 2009),
including cancer, and kinases represent 20% of all putative drug
targets (Futreal et al., 2004; Hopkins and Groom, 2002). Under-
standing the mechanisms that control kinase activity and sub-
strate specificity is therefore of central interest to biomedical
research. Studies using classical biochemical approaches
have shown that kinases exert their function in the context of
kinase protein complexes formed by specific associations with
a range of other proteins, including regulatory subunits, kinase
inhibitors, scaffold proteins, and proteins that target the complex
to specific subcellular sites, as well as substrates. In spite of their
eminent biological importance and in contrast to the situation in
yeast, where several large-scale affinity purification and mass
spectrometry (AP-MS) studies have provided insight into how
the yeast kinome is connected to other proteins (Breitkreutz
et al., 2010; Gavin et al., 2006), our general knowledge of human
protein kinase complexes is very limited. This is due to the focus
of small-scale studies on kinases that have been genetically
linked to essential processes or diseases, and the lack of global
studies on human kinase complexes (Edwards et al., 2011).
Investigators have used an array of techniques to determine
protein-protein interactions (PPIs) and define protein complexes.
Currently, however, AP-MS is the only method that is capable of
isolating and identifying protein complexes from human cells un-
der near-physiological conditions (Gingras et al., 2007). Recent
advances in AP protocols, MS instrumentation, and computa-
tional tools resulted in the identification of high-confidence
interaction (HCI) proteomes of different human protein groups
(Behrends et al., 2010; Breitkreutz et al., 2010; Choi et al.,
2011; Glatter et al., 2009; Sardiu et al., 2008; Sowa et al., 2009).
Here we present a systematic protein interaction study of
the human CMGC (cyclin-dependent kinase [CDK], mitogen-
activated protein kinase [MAPK], glycogen synthase kinase
[GSK3], CDC-like kinase [CLK]) group of protein kinases. This
evolutionarily conserved group consists of 62 members (http://
uniprot.org), which are assigned to nine families. The CDKs
andMAPKs are the two largest and best-studied CMGC groups.
Besides control of the cell cycle, CDKs are known to control
the activity of human tumor suppressors and thus have been
of prime interest in molecular cancer research. The MAPKs
regulate a variety of cellular processes and participate exten-
sively in the control of cell-fate decisions across all eukaryotic
phyla. Other interesting CMGC families include the dual-speci-
ficity tyrosine-regulated kinases (DYRK) and the serine-arginine
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protein kinases (SRPK); however, these kinases are much less
studied and only sparse information on how they engage in inter-
actions with other proteins is available in public databases.
In this work, we systematically determined the protein interac-
tions of all of the 57 CMGC kinases expressed in human tissues
(http://genesapiens.org). CMGC kinase group members fre-
quently have related interaction profiles that are enriched for
specific Gene Ontology (GO) groups that link the CMGC kinase
families to various biochemical processes in transcription, RNA
processing, cellular communication, the regulation of the cell
cycle, and more. The most prominent protein group among
CMGC-binding proteins is the kinases themselves, suggesting
that the human kinome as a whole forms large regulatory net-
works. Here we present a combined computational and experi-
mental approach for identifying kinase-substrate candidates.
Finally, the identified biochemical context points to a multitude
of molecular links between CMGC kinases and proteins associ-
ated with human diseases. We note that several groups of pro-
teins that are linked to similar disease phenotypes tend to cluster
around specific CMGC kinase complexes. We found an overrep-
resentation of cancer-associated proteins (CAPs) in CMGC
kinase complexes. Therefore, this work represents an important
resource to direct future studies aimed at identifying approaches
to interfere with human pathologies linked to perturbed CMGC
interaction proteomes.
RESULTS AND DISCUSSION
Systematic Analysis of Human CMGC Kinome
Complexes
Despite their central role in the control of biological processes
and diseases, human protein kinases have not previously been
subjected to a systematic analysis. Here, we applied a recently
developed, integrated experimental and computational AP-MS
method to characterize the human CMGC kinase interactome
(Breitkreutz et al., 2010; Choi et al., 2011; Glatter et al., 2009).
The method is schematically illustrated in Figures 1A–1C. We
generated isogenic HEK293 cell lines for each of the 57 studied
kinases, and the kinase in question was inducibly expressed with
a Twin-Strep-tag and hemagglutinin (SH) tag (Table S1) to a level
that approximately matched that of the intrinsic kinase (Glatter
et al., 2009; Figure S1). Kinase complexes were purified by
double-AP and tryptic peptide samples were subjected to liquid
chromatography-MS (LC-MS) in technical replicates (overall
reproducibility > 86%).
The double-AP yielded less background contaminants but had
similar sensitivity compared with the single Strep purification
(Figures S1C and S1D). We used the generated LC-MS data to
identify the sample proteins, which we then further classified
as high-confidence interacting proteins (HCIPs) or nonspecific
interactors using the recently developed SAINT algorithm (Choi
et al., 2011; Figures 1A–1C). Overall, the AP-MS analysis of the
57CMGCgroupmembers resulted in a high-confidence network
of 481 proteins and 652 kinase-protein interactions (for details on
filtering, see Tables S1 and S2).
We applied two independent methods—coimmunoprecipita-
tion (coIP) in HEK293T cells and bimolecular fluorescence
complementation (BiFC) assays in HeLa cells—to validate the
specificity of the obtained CMGC interactome data set (Figures
S2 and S3). Twenty-three tested interactions were validated
with either coIP or BiFC, and 19 of 23 (83%) were validated
with both of the tested methods, which corresponds well to
the validation rates reported recently in other HCIP studies using
AP-MS (Behrends et al., 2010; Sowa et al., 2009).
On average, CMGC kinases undergo complex formation with
11 HCIPs (Figure 1D). This number is similar to what has been
reported for other human baits in large-scale AP-MS studies
(Behrends et al., 2010; Sowa et al., 2009). The number of HCIs
per bait, however, varies significantly across the different
CMGC families. SRPKs showed more than three times the
number of binding partners per bait compared with other
CMGC kinases, whereas CDKL and RCK kinases revealed only
a few binding partners (Figure 1E). The largest CMGC family,
CDK, interacts with almost half of the CMGC interaction network
components (219), but the average number of interactions per
bait in the CDK family does not deviate from the average.
The functional diversity of the CMGC kinase-binding proteins
is illustrated in a network graph in Figure 1F, where interacting
proteins are grouped based on their GO classifications (simpli-
fied GO Biological Processes [GO-BP]; Keshava Prasad et al.,
2009). Since the CMGC group includes kinases with established
roles in cell-cycle regulation and signaling, it is not surprising that
many CMGC HCIPs have functions in cell communication (80
HCIPs), cell growth (24), and cell cycle (19). An unexpectedly
large number of HCIPs are involved in transcription and RNA-
related processing (147 [31% of all the HCIPs]; Figure 1F).
Subsequent hierarchical clustering based on GO-BP (Figure 1G)
and GO Molecular Functions (GO-MF; Figure S4) revealed that
CDK family members, as expected, preferentially bind to pro-
teins associated with cell-cycle regulation. As many as 51% of
CMGC kinases have a minimum of three HCIPs associated
with cell communication or signal transduction. The other large
ontology group in the CMGC interactome is ‘‘regulation of
nucleic acid metabolism,’’ which covered 53% of HCIPs linked
mainly to complexes of SRPKs and CLKs. The GO-BP analysis
links many poorly studied kinases to distinct cellular functions.
For example, proteins that bind to DYRK1A and DYRK1B have
roles in the regulation of cell growth, a function that was not pre-
viously reported for these kinases.
Comparison with Previously Identified CMGC Kinase
Interactions, and the Modular Topology of the CMGC
Interactome
Overall, we identified 531 protein interactions for CMGC kinases
and 121 interactions already annotated in public interaction
databases (Cowley et al., 2012; Turner et al., 2010). We also esti-
mated the fraction of public interactions not covered by our
study. However, an objective evaluation of PPI data coverage
is complicated by the heterogeneous source and the unknown
false-positive rate of public PPI data. To address these issues,
we used public data annotated in the PINA database (Cowley
et al., 2012), which allowed us to filter the public interactome
for the number of independent reports supporting a given inter-
action as a proxy for data robustness. When we considered all
physical PPIs (including yeast two-hybrid data) supported by
at least two independent reports, our study covered 16% of
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public PPI data. However, the coverage moved up to 49% when
we considered only robust PPIs that are supported bymore than
six publications (for details see Table S2). We also found that the
public interactions that overlapped with our study were pub-
lished on average 10.7 times, in contrast to the set of public in-
teractions not found in our study, which were referenced only
2.9 times on average. This illustrates the overall robustness of
the presented PPI data.
The overlap between our data and already reported interac-
tions varies significantly across the different CMGC members
(Figure 2A). This can be explained by the fact that various families
have been studied to different extents and by different methods
in the past.
The DYRKs are a particularly rich source for interaction infor-
mation. The DYRK subnetwork is composed of 60 proteins
and 78 interactions, of which only two could be found in public
databases (Figure 2B). Most of the interactions we found consti-
tute complexes containing the highly related class I family
members DYRK1A and DYRK1B. DYRK1A and DYRK1B com-
plexes have 20 proteins in common, and these proteins are not
Figure 1. Proteomic Analysis of CMGC Kinase Complexes
(A–C) Schematic overview of (A) the generation of the 57 isogenic HEK293 cell lines for inducible expression of SH-tagged CMGC bait kinases, (B) double-AP
strategy and LC-MS/MS analysis of the purified kinase complexes, and (C) identification of HCIs from AP-MS data using statistical filtering.
(D) Distribution of the number of HCIs identified across CMGC kinases (baits).
(E) Average number of HCIs for each CMGC kinase family.
(F) Network model of the CMGC kinase interaction landscape. The CMGC kinase families are organized based on their sequence similarity and the HCIPs are
grouped according to their simplified GO process annotation.
(G) Hierarchical clustering of CMGC kinases and GO-BP terms associated with the corresponding HCIPs. The color gradient illustrates the number of HCIPs
assigned to each particular GO term.
See also Figure S1 and Table S1.
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Figure 2. Relationship of the CMGC AP-MS Data to Previously Published PPI Information
(A) Overview of HCIs identified in CMGC kinases. Interactions identified in this study are shown in blue, and red indicates the PPIs reported in public databases.
(B) Comparison of DYRK interactomes. Known interactions between the HCIPs are shownwith a dotted line. Sequence similarity between DYRK family members
is illustrated as a dendrogram (upper panel).
(C) Overview of HCIs of individual CMGC kinases grouped with their corresponding families.
(D) A subnetwork of the CDK2 interactome illustrates the interactions with cyclins (green), CDK inhibitors (red), regulatory subunit (light blue), components of the
SCF (blue), and Rb family members (gray).
(E) CDK11A interacts with CKII subunits (red), RNA-binding proteins (turquoise), zinc finger proteins (blue), and importin subunits (lilac).
See also Figures S2 and S7, and Tables S2 and S7.
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found in complexes with the class II family members DYRK2,
DYRK3, and DYRK4. For example, DYRK1A and DYRK1B com-
plexes both contain LZTS2, a putative tumor suppressor that
suppresses Wnt signaling by promoting nuclear exclusion of
CTNNB1 (Thyssen et al., 2006). We also found interesting differ-
ences between DYRK1A and DYRK1B. For example, DYRK1B
complexes contain MYST1 and MSL3, two proteins from the
human MSL complex that are involved in chromatin remodeling,
and ARNTL, a bHLH-PAS transcription factor that is essential for
the control of circadian rhythm (Bunger et al., 2000). Further-
more, DYRK1B kinase complexes contain the oncogene c-SKI,
which binds the SMAD complex and suppresses the transform-
ing growth factor b (TGFb) target gene promoter (Akiyoshi et al.,
1999; Javelaud et al., 2011). In contrast, DYRK1A was found
in complexes containing the farnesyltransferases FNTA and
FNTB. The interactomes of the class II members DYRK2,
DYRK3, and DYRK4 are quite different from each other. They
form fewer interactions and only two proteins (TECR and
USP11) are shared with class I DYRK complexes. The observed
differences are consistent with the idea that class I and class II
DYRKs diverged early in evolution (Aranda et al., 2011) and
have undergone functional diversification by acquiring new pro-
tein interactions.
The public interaction data indicated that a number of kinases
display a highly interlinked modular topology, suggesting that
these proteins are organized in larger complexes. This was
apparent within the SRPK, CLK, and CDK families (Figure 2C).
Among the 131 proteins associated with SRPK and the related
CLK family members, we found proteins that partition in several
distinct RNA processing complexes, including the Nop56p-
associated pre-rRNA complex; the U2, U4/U6, and U5 spliceo-
some complexes; and the EJC/TREX complex (Hayano et al.,
2003; Hegele et al., 2012). Among the well-studied CDK family
members, we could identify expected complexes with regulatory
subunits, cyclins, and CDK inhibitors. Figure 2D illustrates the
interactions found for CDK2. For poorly studied CDK family
members, we found a higher fraction of previously unknown
additional interactions. CDK11A, for example, revealed interac-
tions with casein kinase subunits, a panel of zinc finger tran-
scription factors, and nuclear transport proteins, which point to
previously unrecognized roles for CDK11A in the control of tran-
scription and nuclear transport (Figure 2E).
Relationships among CMGC Interaction Proteomes
To analyze the relationships among the interactomes of
different CMGC group members, we performed hierarchical
clustering of CMGC kinases and their HCIPs (Figure 3A). We
found that individual CMGC kinases can form unique com-
plexes that are highly specific for that particular kinase, such
as CDK7 or nemo-like kinase (NLK). We also noticed that
related kinases often share a significant fraction of HCIPs.
Closer inspection of these related interactomes revealed inter-
esting differences that may point to different biochemical roles
for related CMGC group members. For example, GSK-3 a
(GSK3A) and GSK-3 b (GSK3B) share many HCIPs (specifically
GSKIP, FRAT1, PPP1R2, AXIN1, AXIN2, and PRKACA) that are
bound even with similar relative abundances as estimated by
spectral counting (Figure 3B). However, only GSK3B could be
detected in complexes with b-catenin (CTNNB1) and adenoma-
tous polyposis coli (APC; Figure 3B), indicating a nonredundant
function of GSK3B in Wnt signaling. This finding is consistent
with the key role assigned to GSK3B in regulating Wnt/
b-catenin signaling. In the absence of Wnt signaling, GSK3B
binds to the ‘‘destruction complex,’’ which in addition contains
AXIN1, APC, and casein kinase I (CKI). As part of this complex,
GSK3B phosphorylates b-catenin, leading to its subsequent
ubiquitination and proteasomal degradation (Dajani et al.,
2003). The GSK3B example illustrates how subtle difference
in protein complex formation may result in functional diversifica-
tion. It also suggests that such specific differences in the
presented PPI data may be helpful for functionally dissecting
other highly related CMGC group members that are less well
characterized than GSK3B.
CDK-Containing Transcription Complexes
Three members of the CDK family (CDK7, CDK8, and CDK19)
form complexes with established roles in basic RNA pol II tran-
scription. We noted that the identified HCIPs of CDK7 (CDK8
and CDK19) were highly connected based on public PPI data,
indicating the formation of large complexes engaged in tran-
scription. Since complex formation with these three kinases
has been well studied in the past, we used these examples to
benchmark the robustness and sensitivity of our experimental
approach. CDK7 is known to form a trimeric complex with cyclin
H (CCNH) and MNAT1 (Figure 3C), also referred to as the CDK-
activating kinase or CAK (Kaldis, 1999). CAK phosphorylates
other CDKs within the activation segment (T-loop) and acts as
a component of the general polymerase II transcription factor
TFIIH, where it phosphorylates the C-terminal domain of the
RNApol II large subunit (Roy et al., 1994; Figure 3C). The helicase
xpd/ERCC2 plays a structural role in tethering the CDK7-cyclin
H-MNAT1 trimer to the core subunits of TFIIH (Chen et al.,
2003; Coin et al., 1999). Our analysis revealed all ten subunits
of TFIIH and CAK, of which the CAK subunits represent the
most abundant protein interacting with CDK7 (Gibbons et al.,
2012).
Figure 3. Hierarchical Clustering of the CMGC HCIPs
(A) Heatmap generated from hierarchical clustering of the 481 HCIPs and the 57 CMGC kinases reveals clusters of related kinases that share interactions.
The color of each individual HCIP (rows) corresponds to its relative abundance, quantified using normalized spectral counts, in each CMGC kinase complex
(columns).
(B) GSK3A and GSK3B form overlapping but also distinct interactions, reflecting their different roles in Wnt signaling.
(C) CDK7, a component of the general transcription factor TFIIH, has a unique interactome ‘‘fingerprint’’ comprised exclusively of interactions with the
components of the TFIIH complex.
(D) CDK8 and CDK19 form a highly related cluster that corresponds to the transcriptional MED complex. The MED complex associates in a mutually exclusive
manner with either CDK8 or CDK19. Blue edges indicate interactions identified in this study and known interactions are shown by black dotted lines.
See also Figure S3.
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CDK8 and CDK19 and their regulatory subunit cyclin C
(CCNC) are components of theMediator (MED) coactivator com-
plex (Sato et al., 2004). The precise composition of this subunit,
as well as potential differences in MED complex formation, has
not been described yet. The MED complex supports transcrip-
tional activation via binding to the activation domain of transcrip-
tion factors and to the general pol II transcription machinery. The
MED core is composed of a head module, a middle module, and
a tail module (Guglielmi et al., 2004), and can bind to RNA poly-
merase II (pol II) to form a holoenzyme. Alternative forms of the
MED complex have been proposed that are free of pol II but
include a kinase module, Cyclin C, and two additional subunits:
MED12 and MED13 (Guglielmi et al., 2004). The two additional
core complex subunits, MED25 andMED26, which function spe-
cifically in transcriptional activation, are not present in the
kinase-associated MED (Ding et al., 2009; Yang et al., 2004).
Consistent with this model, we found that both CDK8 and
CDK19 form mutually exclusive complexes with all subunits of
the alternative form of MED complex lacking MED25 and
MED26. In addition, we found that CDK8 and CDK19 associate
with the MED subunits in similar relative amounts, as estimated
from normalized spectral counts (Figure 3D), indicating that the
two paralogous kinases do not undergo differential MED com-
plex formation. The presented data represent themost complete
set of interactions between the CDK8/19 and MED subunits
currently available, and illustrate the robustness and sensitivity
of the experimental and computational workflow used in this
study.
Topology of CMGC Kinase-Kinase Interactions
We next clustered the occurrence of specific structural domains
in the proteins found in CMGC kinase complexes across all
CMGC kinases (Figure 4A). The most frequently found domains
were the RNA recognition motif (RRM) domain (n = 55) and pro-
tein kinase domain (n = 45). The majority of proteins containing
an RRM domain were associated with SRPKs and CLKs.
Remarkably, almost half of the CMGC kinases were interacting
with proteins that contain a protein kinase domain, suggesting
that human CMGC kinases have a previously unidentified prefer-
ence for interacting with other protein kinases, which is reminis-
cent of the kinase-kinase network reported in a global analysis of
yeast kinase complexes (Breitkreutz et al., 2010).
To illustrate the kinase-kinase interactions in more detail, we
combined all detected kinase-kinase interactions with published
interaction information for the identified kinases in a network
graph (Figure 4B). Remarkably, the majority of the kinase-kinase
interactions (n = 44 interactions) represent CMGC kinases inter-
acting with other CMGC kinases. The second-largest kinase
group is the CAMK group (n = 24 interactions), followed by the
AGC group (n = 13 interactions). Most of the previously reported
kinase-kinase interactions clustered around the MAPK family.
The presented kinase-kinase network provides insights into the
organization of kinases into large regulatory kinase-kinase net-
works, and the mechanism of multisite substrate phosphoryla-
tion by kinase-kinase complexes.
Inferring Regulatory Networks within the CMGC
Interaction Proteome
Protein phosphorylation requires the formation of transient or
stable kinase-substrate complexes. The obtained AP-MS data
may therefore include new kinase-substrate relationships. In
order to narrow down the potential kinase-substrate space, we
pursued the following strategy: First we compiled all phospho-
peptides identified from the CMGC AP-MS data and all phos-
phopeptides from CMGC network nodes available from public
data (Hornbeck et al., 2012). Second, we predicted upstream
kinases for these phosphosites using the NetworKIN algorithm
to construct a hypothetical kinase-substrate network (Linding
et al., 2007). Finally, we merged this predicted network with
the CMGC AP-MS data to identify those kinase-protein interac-
tions that intersect with the predicted kinase-substrate interac-
tion and thus may represent high-confidence kinase-substrate
interactions.
In total, we identified 1,315 phosphopeptides (false discovery
rate [FDR] < 1%) corresponding to 503 unique phosphosites in
106 unique proteins from the CMGC AP-MS data. Of the 503
phosphosites identified, 380 had been reported previously (Fig-
ure 5A; TableS3). A large fraction (188/503) of the identified phos-
phosites was detected in protein kinases, and a fractionmapped
to the activation loop region in the CMGC kinases (Figure S5).
When we combined our data with public phosphosite informa-
tion, we obtained a total of 1,789 phosphosites for the 481
CMGC network components (Figure 5B; Hornbeck et al.,
2012). Using NetworKIN, we could predict candidate upstream
kinases for these sites (Table S4). Overall, our PPI data inter-
sected with 47 predicted kinase-substrate interactions. In addi-
tion to the kinase-substrate interaction predicted by NetworKIN,
our AP-MS data overlapped with 23 experimental kinase-sub-
strate interactions (Hornbeck et al., 2012), resulting in a total
overlap of 56 interactions between 17 kinases and their candi-
date substrates (Table S4). From the intersecting candidate
kinase-substrate network (Figure 5C) we identified several regu-
latory modules where a kinase could be assigned to a set of
candidate substrates (Figure 5C). For example, the relatively
poorly studied kinase CLK2 is associated with ten candidate
substrates, the majority of which can be linked to RNA process-
ing and transcription. Furthermore, our analysis revealed several
GSK3B sites on three components of theWnt signaling pathway,
Figure 4. CMGC-Kinase-Kinase Highway
(A) Hierarchical clustering of protein domains present in the CMGC interacting proteins. The domains foundmost frequently within CMGC interacting proteins are
highlighted. The color gradient corresponds to the number of unique proteins that contain a particular domain and interact with an individual CMGC kinase.
(B) Network model illustrating physical interactions between CMGC kinases and other kinase family members. Node color corresponds to the kinase families
shown in the pie chart. The pie chart shows the distribution of interactions between various kinase family members and CMGC kinases. Dashed lines illustrate
interactions from the public databases, and solid edges represent known (blue edges) and additional (red edges) kinase-kinase interactions found in the AP-MS
data set.
See also Figure S4.
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including the evolutionary conserved residues S33, S37, and T41
on b-catenin (Liu et al., 2002); the APCphosphorylation on S1501
(Ferrarese et al., 2007); and S188 of the proto-oncogene FRAT1
(Hornbeck et al., 2012). Besides Wnt signaling components, we
also found Protein phosphatase inhibitor 2 and Protein kinase
A-anchoring protein 11 (AKAP11) as candidate GSK3B sub-
strates. The cyclic AMP-dependent protein kinase (PRKACA)
and its regulatory subunit PRKR1A were also found in GSK3B
complexes, and PRKACA has been proposed to phosphorylate
GSK3B on S9 (Hornbeck et al., 2012).
The largest candidate kinase-substrate networks from our
analysis were found for CDK2, which suggests 14 substrates
(eight that have already been annotated as in vivo or in vitro sub-
strates, and six that represent additional substrate candidates
[CREBBP, CDKN1C, CCNB1, GOLGA2, CCNE2, and CDK13]).
The same approach also identified kinases predicted to phos-
phorylate other kinases in their T-loop (also referred to as the
activation loop) region and thus could act as upstream activating
kinases in regulatory networks. The examples identified revealed
a MAPK signaling module in which MAPK family members
appear to be sequentially phosphorylated at their T-loop site
by other MAPK family members (Figure 5C).
Consistent with our findings, MAP2K3 (also known as MKK3)
is known to activate MAPK14/p38-MAPKa via T-loop phosphor-
ylation of T180 and Y182 of MAPK14 (De´rijard et al., 1995;
Raingeaud et al., 1995). Following its activation, MAPK14 can
phosphorylate a number of substrates, including other MAPK
family members (Cuadrado and Nebreda, 2010). Our analysis
showed that MKNK1 and MAPKAP3 form stable complexes
with the two p38 kinases (MAPK14 and MAPK11) and are pre-
dicted to be phosphorylated in their T-loop region by the associ-
ated p38 kinases. By applying the combined AP-MS/NetworKIN
analysis, in addition to known p38 substrates (e.g., EEF2 and
RPS6KA4), we identified additional candidate substrates. These
include the candidate MAPK14 substrates USP11 (a deubiquiti-
nating enzyme implicated in NF-kappa-B activation; Yamaguchi
et al., 2007) and IQGAP1 (implicated as a scaffold for MAPK
signaling; Roy et al., 2004, 2005), as well as the MAPK11 candi-
date substrates ARHGAP12 (a Rho-type GTPase-activating pro-
tein) and Cul7 (an Skp, Cullin, F-box-containing complex [SCF]
E3 ubiquitin ligase component that is genetically linked to 3-M
syndrome; Huber et al., 2005).
An SRPK-Substrate Network Is Linked to RNA
Processing
Substrate prediction tools such as NetworKIN and Scansite do
not cover SRPKs because only a few substrates are known for
the SRPK family and prediction is complicated by a mechanism
of progressive substrate phosphorylation of multiple serines
(Aubol et al., 2003). To identify candidate substrates for SRPK1
and SRPK2, we used two criteria. The first is the ability to recon-
stitute substrate phosphorylation in vitro, and the second is the
physical association of the kinase with its substrate in vivo. We
performed systematic in vitro kinase (IVK) assays with SRPK1
and SRPK2 on protein microarrays containing >9,000 unique
human proteins (Figure 6A) and combined the results from these
experiments with the SRPK1/2 AP-MS data (Figure 6B). Using a
Z-score cutoff of 0.25, we identified 155 and 160 IVK substrates
for SRPK1 and SRPK2, respectively (Table S5). We found differ-
ences between SRPK1 and SRPK2, but also 72 shared sub-
strates (Figure 6B). Furthermore, the identified IVK substrates
were highly enriched for known splicing proteins (p = 1.80E-15;
Figure S6; Table S6). Among the three annotated substrates for
SRPK1andSRPK2 thatwerepresenton themicroarray,wecould
confirm SRSF1 and RBM8A as in vitro substrates. Besides
SRSF1, we identified 26 proteins linked to messenger RNA
(mRNA) splicing, 22 of which could be assigned to distinct func-
tional groups involved at different stepsofmRNAsplicing (Hegele
et al., 2012; Figure 6C). We noticed a significant overlap between
the proteins identified by IVK experiments and AP-MS. The inte-
gration of SRPK1 and SRPK2 IVK-substrate relationships with
the AP-MS data resulted in a networkmodel that consists almost
exclusively of proteins involved in mRNA splicing or RNA
processing (Figure 6D, light orange), 11 of which have been
described recently as components of the exon junction com-
plexes (EJC) interactome (Singh et al., 2012). These data suggest
that SRPK protein binding and kinase activity may be required to
coordinate distinctmolecular events involved inRNAprocessing.
Disease Phenotypes Linked to the CMGC Interaction
Proteome
The systematic mapping and high-throughput sequencing of
human disease loci provides insights into the role of cellular pro-
teins in human pathogenesis. However, the mechanistic basis of
how genomic lesions are translated into disease phenotypes is
poorly understood. We therefore integrated the information on
disease loci with the CMGC kinase-protein interaction data to
better understand how kinases may control disease pathways,
and to uncover modules of biochemically related proteins linked
to a specific disease phenotype.
Using annotated genetic disease information (OMIM and
COSMIC), we queried the CMGC AP-MS data set for the
presence of disease-associated proteins (DAPs) and studied
the topology of a protein interaction network formed between
kinases and DAPs. Altogether, we identified 91 DAPs that phys-
ically interacted with CMGC kinases, forming a network of 143
interactions (Figure 7A). By far themost prominent disease group
we found in the CMGC interaction proteome was cancer. Other
Figure 5. Candidate CMGC Kinase-Substrate Network Predicted by a Combined Proteomics and Computational Approach
(A) CMGC AP-MS analysis revealed 503 unique phosphosites, 123 of which have not been detected before.
(B) Computational strategy to predict upstream kinases for the phosphosites present in the CMGC network components. Phosphosites found in this study were
combined with annotated phosphosites to predict candidate kinase relationships using NetworKIN. The predictions were filtered for kinase-substrate pairs that
also form stable complexes based on the CMGC AP-MS data set.
(C) Network diagrams illustrating kinase-substrate interactions (red edges) intersecting with the AP-MS data set (blue edges). Nodes in the enlarged network
graphs illustrate kinases (blue), substrates (blue), and phosphorylation sites (orange). T-loop phosphorylation sites are indicated as green nodes. Edges pointing
toward the phosphorylation sites indicate known (orange) or predicted (opaque orange) phosphorylation events.
See also Figure S5 and Tables S3 and S4.
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diseases linked to CMGC complexes includemental retardation,
microencephaly, retinitis pigmentosa, xeroderma pigmentosum,
and 3-M syndrome. If a group of proteins constitute a specific
complex that is linked to a particular disease pathway, it is
conceivable that mutations in the corresponding complex sub-
units might result in a similar disease phenotype. We therefore
analyzed the CMGC interaction proteomes for cases in which
a particular disease phenotype was clustered around specific
kinase complexes. Despite the limited availability of genetically
mapped disease information and the likely incompleteness of
the AP-MS interaction data, we could identify five clusters in
which a group of proteins binding to a particular CMGC kinase
mapped to a specific disease phenotype (Figure 7A). Specif-
ically, all proteins in the CMGC network (PRPF8, SNRNP200,
PRPF31, and PRPF6) associated with retinitis pigmentosa,
a progressive retinal dystrophy, were exclusively found in com-
plexes with PRPF4B. Likewise, we found Cul7, CCDC8, and
OBSL1—three proteins that are associated with 3-M syndrome,
a primordial growth retardation disorder (Hanson et al., 2011)—in
complexes with the p38 MAPKs MAPK11 and MAPK14.
Overall, 43 kinase-associated proteins identified in the AP-MS
data set are genetically linked to various forms of human cancer.
The observed frequency is about three times higher than ex-
pected from a random network of similar topology (Figure 7A,
inset). Several CMGC kinases qualified as ‘‘cancer hubs’’ with
multiple interactions to cancer-linked proteins. Similarly to the
examples described above, some of these ‘‘cancer hubs’’
were associated with a set of cancer proteins pointing to a
particular type of cancer. For example, and in agreement with
previous results, we identified three proteins (ERCC2, ERCC3,
and ERCC5) in CDK7 complexes that are linked to xeroderma
pigmentosum, an autosomal recessive genetic disorder that is
linked to severe DNA repair defects and causes severe UV sensi-
tivity with increased risk for skin cancer (Giglia-Mari et al., 2004;
Jeronimo et al., 2007). Moreover, all of the five proteins (MLLT1,
MLLT3, AFF1, AFF3, and AFF4) linked to acute lymphoblastic
leukemia (ALL) and acute myeloid leukemia (AML) in the
CMGC network were identified in complexes with CDK9 (Fig-
ure 7B). In ALL and AML, the genes of these CDK9-binding pro-
teins undergo translocation with the histone methyltransferase
MLL. It is believed that these diseases are caused by epigenetic
changes that lead to overproliferation of immature white blood
cells (Benedikt et al., 2011).
Other CMGC kinases associate with multiple cancer proteins
that are linked to various cancer types. CDK6, for example, has
been found in complexes with the cyclin D2 (CCND2), cyclin
D3 (CCND3), and CDK inhibitor p18-INK6 (CDKN2C) linked
to various tumor types, including non-Hodgkin lymphomas
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Figure 6. SRPK1 and SRPK2 Physically and Functionally Interact with Different Classes of mRNA-Processing Proteins
(A) Identification of SRPK1 and SRPK2 IVK substrates using protein microarrays.
(B) Venn diagrams illustrating substrates and binding partners shared by SRPK1 and SRPK2.
(C) SRPK1 and SRPK2 IVK-substrate network involving distinct functional groups engaged during various steps of mRNA splicing.
(D) Integration of data from IVK assays and AP-MS data reveals a functional network involved in various steps of RNA processing (light orange nodes).
Components of the EJC interactome are indicated in red.
See also Figure S6 and Tables S5 and S6.
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(CCND2) and gliomas (CDKN2C). Likewise, GSK3A and GSK3B
interact with a set of proteins linked to colon cancer (APC and
CTNNB1), hepatocellular carcinoma (AXIN1), and thyroid carci-
noma (PRKAR1A; Forbes et al., 2008). Importantly, besides
these established cancer protein interactions, our data revealed
previously unrecognized interactions with CAPs and less studied
kinase subfamily members such as CLK2 and SRPK2. CLK2, for
example, forms interactions with three CAPs, including SETD2, a
histone lysine N-methyltransferase that was recently linked to
renal carcinoma (Dalgliesh et al., 2010). Likewise, SRPK1 and
SRPK2 interact with THRAP3, SRSF2, and U2AF1, and both
SRSF2 and U2AF1 are linked to chronic lymphocytic leukemia
(CLL), the second most common adult leukemia (Figure 7C). In
addition, NLK forms complexes with five DAPs, including
SMAD4, a protein that has been found to be significantlymutated
in humanpancreatic cancer (Figure 7D;Biankin et al., 2012; Hahn
et al., 1996). Becausemost of these interactions between CMGC
group members and DAPs have not yet been reported in public
interaction databases, the presented kinase-DAP interactome
represents a rich source for developing novel hypotheses about
the control of disease pathways by CMGC kinases.
Concluding Remarks
In this work we have provided a comprehensive analysis of the
CMGC kinase interaction proteome. Our study reveals 531 pro-
tein interactions for the CMGC kinase group and confirms 121
previously described interactions, suggesting that the previously
annotated interaction proteome for CMGC kinases, and thus for
the human kinome in general, is far from being complete. The
interactions we found are not equally distributed across the
CMGC kinase families but are enriched in subgroups that are
poorly represented in the current literature, such as the CLK,
HIPK, and DYRK families. This indicates that the protein-interac-
tion information for the CMGC kinase group that is available in
public databases is biased toward well-studied kinases. This
bias, together with limited interaction information, restrains the
development of models for regulatory pathways, highlighting
the need for systematic AP-MS studies to fill the gaps in our
knowledge about poorly studied protein groups.
Comparisons of orthologous protein-interaction data across
species can provide insights into evolutionary conservation and
changes in protein interactions and complexes. We compared
the CMGC interaction data from our study with orthologous
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Figure 7. Complex Formation between CMGC Kinases and Human Disease Proteins
(A) Physical interactions between CMGC kinases and proteins associated with human diseases. Known interactions are indicated by blue edges, and additional
interactions are highlighted in red and. Modules containing CMGC kinase-associated proteins genetically linked to the same disease phenotype indicated in
the figure are highlighted as orange squares. Inset at the bottom illustrates enrichment of cancer proteins in the CMGC interactome (green dotted line; n = 43;
p < 0.001) compared with the distribution of CAPs occurring in 10,000 random networks (481 proteins, 652 interactions).
(B) CDK9 interacts almost exclusively with proteins mutated in ALL.
(C) SRPK2 complex formation with human DAPs.
(D) DAPs in complexes with NLK. Numbers in parentheses refer to OMIM IDs.
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interaction data from budding yeast because yeast represents
the only eukaryotic organism for which proteome-wide interac-
tion data are currently available. We found conservation around
complexes of the CDK, MAPK, DYRK, SRPK, and CLK families,
but not for the other CMGC families (Figure S7; Table S7).
Approximately half of the orthologous interactions represented
in the current yeast interactome involve CDKs. They constitute
highly conserved complexes with cyclins and CDK regulatory
subunits, TFIIH, or transcriptional MED complexes involved
cell-cycle control and transcription, two basic biological func-
tions. Also, the orthologous interactions within manyMAPK fam-
ily members are well represented in existing yeast interaction
data and indicate an expansion of orthologous human MAPK
complexes compared with yeast. In contrast, orthologous inter-
actions with other family members are poorly represented in the
known yeast interactome or are not present at all (GSK3A,
GSK3B, HIPK4, and PRPF4B). These differences may indicate
evolutionary changes in the human interaction landscape, but
to some extent theymay also reflect limitations in protein interac-
tion data coverage. The presented data will facilitate efforts to
understand the functional diversification of a related group of
kinases by means of alternative complex formation. We noted
diverse but also highly related complex formation among closely
related CMGC groupmembers, which indicates functional diver-
sification but also redundancy of certain CMGCkinases.With the
contextual information presented here, it is now possible to
assign poorly characterized kinases to a specific functional
context and expand the potential roles of someof the established
CMGC group members. The CMGC interaction proteome may
include regulators of kinase activity as well as novel
kinase substrates. Obtaining reliable kinase-substrate informa-
tion represents a major challenge in the development of novel
regulatory pathway models to elucidate cellular regulation in
health and disease. To this end, we could show that at least a
fraction of kinase-associated proteins can also serve as kinase
substrates. Despite obvious restrictions imposed by complex
stability during AP, the limited dynamic range of MS analysis,
and the limited signaling states represented in exponentially
growing HEK293 cells, we were able to identify, besides well-es-
tablished kinase substrates, a number of candidate kinase sub-
strates by using an integrated proteomics and computational
approach. In parallel, by using a protein microarray approach,
we also showed that a significant fraction of proteins identified
in complexes of the SRPK group also act as kinase substrates
in vitro.
Kinases represent 20% of current drug targets and have been
genetically linked to a number of human disease phenotypes,
including cancer (Hopkins and Groom, 2002). Compounds that
either enhance or inhibit disease-relevant kinase-protein interac-
tionsmay provide a promising but as yet poorly explored route to
modulate kinase networks that are perturbed in human diseases.
The CMGC interaction proteome revealed 108 physical interac-
tions between CMGC group members and human DAPs not
found in public databases. The distribution of disease pheno-
types across the interaction landscape revealed several specific
diseases that were clustered around particular kinases and thus
may provide clues to the role of protein complexes in controlling
the emergence of specific disease phenotypes. Proteins associ-
ated with human cancer were enriched in the CMGC kinase
network, which may hint at a role of the CMGC interaction prote-
ome in controlling tumor cell growth. Therefore, the presented
CMGC interaction proteome represents a knowledge base for
instructing future functional experiments to uncover the molecu-
lar mechanisms that control human tumor growth by specific
CMGC kinases, which in turn may provide new opportunities
for pharmacological intervention using drugs that modulate the
kinase interaction proteome.
EXPERIMENTAL PROCEDURES
Cell Culture
SH-tagged human CMGC kinases stably and inducibly expressing Flp-In 293
T-Rex cell lines were each expanded to53 107 cells and 1 mg/ml tetracycline
was added for 24 hr to induce expression of SH-tagged bait proteins.
AP of Protein Complexes and MS Analysis
For AP, the 53 107 cells were lysed in 4 ml of lysis buffer (0.5% NP40, 50 mM
Tris-HCl, pH 8.0, 150mMNaCl, 50mMNaF, 1.5mMNaVO3, 5mMEDTA, sup-
plemented with 0.5 mM PMSF and protease inhibitors; Sigma). The cleared
lysate was loaded on spin columns (Bio-Rad) containing 200 ml Strep-Tactin
beads (IBA GmbH) and the beads were washed three times with 1 ml of lysis
buffer. Proteins were eluted from the Strep-Tactin beads with 2 mM biotin, fol-
lowed by incubation of the eluate with 100 ml anti-HA agarose (Sigma) for 2 hr
on a rotation shaker. The anti-HA agarose was washed three times with 1ml of
lysis buffer without protease inhibitor and detergent. Purified protein com-
plexes were eluted with 0.2 M glycine, pH 2.5, and subsequently neutralized
with 100 mM NH4HCO3. Cysteine bonds were reduced with 5 mM Tris(2-car-
boxyethyl)phosphine (TCEP) and alkylated with 10 mM iodoacetamide. The
proteins were then trypsinized to peptides, and the peptides were purified
with C18 microspin columns (Harvard Apparatus).
MS Analyses
The tryptic peptide samples were analyzed on a hybrid LTQ Orbitrap XL mass
spectrometer (Thermo Scientific) using Xcalibur version 2.0.7 coupled to an
Eksigent NanoLC-2D HPLC nanoflow system (dual pump system with one
analytical column; Eksigent) via a nanoelectrospray ion source using a liquid
junction (Thermo Scientific). Each purification sample was analyzed in tech-
nical replicates, and for each replicate 7% of the sample was loaded onto a
15 cm (B75 mm) fused silica analytical column (PicoFrit; New Objective)
packed with C18 reversed-phase material (Magic C18 AQ 3 mm; Michrom
BioResources). The peptides were eluted with 40 min gradient (constant flow
rate of 300 nl/min) ranging from 5% to 35% solvent B, followed by a 10 min
gradient from 35% to 80% solvent B. After every two technical replicate
samples, 100 fmol of control peptide ([Glu1]-Fibrinopeptide B human (Sigma)
was analyzed twice by LC-MS/MS, allowing the standardized monitoring of
the LC-MS/MS system performance, and detection and possible exclusion of
carryover protein (namely, bait protein from the previous sample). Acquired
MS2 scanswere searched against theUniProtKB/Swiss-Prot protein database
(release 12.0) using the XTandem search algorithm (Craig and Beavis, 2004)
with the k-score plug-in (MacLean et al., 2006) for identification of the CMGC
interactome,orwithMascot (MatrixScience) for phosphopeptide identification.
Identification of HCIs
To obtain high-confidence protein-interaction data from AP-MS raw data,
we used Significance Analysis of Interactome (SAINT), which determines the
statistical significance of observed interactions using protein abundance
based on label-free quantification (Choi et al., 2011). The empirical frequency
threshold was set to 0.09 and the iProb threshold value was set to >0.9 for
HCIs. The detailed SAINT input and obtained output files are listed in Table
S1. The filtered CMGC high-confidence data set was further analyzed and
visualized using Cytoscape 2.8.3. Interaction information from the iRefWeb
and PINA database was used to annotate known protein interactions (Cowley
et al., 2012; Razick et al., 2011; Turner et al., 2010).
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Protein Kinase-Substrate Arrays
To identify substrates for kinases, we performed IVK assays on Protoarray
human protein microarrays (version 5.0; Invitrogen). For the IVK assays on
the protein microarray, the array was first blocked and then incubated with
the corresponding kinase (50 nM) in the presence of radiolabeled [g-33P]
ATP. The array was then washed to remove the unbound g-33P, dried, and
exposed to X-ray film. The acquired image of the array was analyzed using
the ProtoArray Prospector software bundle (Invitrogen). The raw data were
subjected to background substraction, signal scatter compensation, and
outlier detection, and the Z factor cutoff value was set at R0.4. Phosphory-
lated proteins with a Z score > 0.25 were considered as potential substrates.
For further details regarding the methods and materials used in this work,
see the Extended Experimental Procedures.
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